Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neffy vs IM Adrenalin for Allergic Reactions After Allergy Challenge
NCT06834165Phase 4Recruiting
- Sponsor
- ARS Pharmaceuticals
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 4 trial of epinephrine nasal spray in allergic reaction (2 arms), sponsored by ARS Pharmaceuticals. Primary endpoint: Adverse Events at 2 hours. Started May 2025; status: recruiting.
02
Drugs
epinephrine nasal spray
03
Conditions
allergic reaction
Beyond the preview
Go deeper on NCT06834165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834165.